Our solutions support medical professionals across the world from different medical specialties. Discover why they chose FibroScan® for their clinical practice.
As a clinical researcher, I rely heavily on FibroScan® to select the right patient for the right study. Clinical trials in non-alcoholic steatohepatitis typically include patients with specific fibrosis stages. It is thus important to have reliable fibrosis assessment and avoid unnecessary liver biopsies.
While performing clinical research in the field of metabolic steatohepatitis, I am constantly asked how I can keep my screening failure rate low. The answer is no secret: FibroScan® examination with SmartExam.
Assessment of liver stiffness and fat by non-invasive method is a huge step forward towards better management of NAFLD. It has hugely impacted the way clinicians stratify the patients, chose therapy and monitor response!
There is very good evidence for using transient elastography by FibroScan® for assessment of fibrosis in alcohol-related liver disease.
Using FibroScan® as an interventional therapy helps primary care physicians and nurse specialists engage patients by demonstrating the results and outcomes as a value change that patients can visualize on a regular basis and give them confidence that their efforts have an impact. […]Weight loss and exercise are the first step in mitigating liver damage.
FibroScan® is perfect for use in a primary care setting, it is portable and gives patients an instant result enabling them to leave knowing the result. It is also a very powerful tool to encourage lifestyle interventions. Using the FibroScan® in primary care enables much wider access to this technology for patients and significantly reduces the cost per scan
In the mobile screening program, the Fibroscan® is both a screening tool and a diagnostic referral tool. It allows us to open up discussion on alcohol and viral hepatitis issues, but also to screen for hepatopathies and organize appropriate follow-up. This tool gives us great autonomy and supports our Risk Reduction approach.
There are strong correlations of liver stiffness with liver fibrosis in Hepatitis C, Hepatitis B, and also in other causes of liver disease such as NAFLD and NASH.
FibroScan® measures stiffness in the liver via VCTE™, which involves a wave of 50Hz entering the liver with an ultrasound acquisition of the shear wave’s transmission speed and velocity. There are other devices on the market that use similar technologies, but FibroScan® is the only device on the market using true transient elastography. The other devices are less validated and certainly do not give us the comfort and reassurance that we have with FibroScan®. In the United States, this is the only device that is approved for use with these indications. I would recommend this as the only real validated technique for the measurement of transient elastography and liver stiffness.
Discover how Juan Pablo Frias, M.D., Medical Director and Principal Investigator at the National Research Institute of Los Angeles (USA) used FibroScan® for clinical trials on NASH.
Discover how Stephen Harrison, M.D., gastroenterologist and hepatologist, medical director of Pinnacle Clinical Research (USA), used FibroScan® and Echosens Scores to identify patients with fatty liver.
Discover the interview of Stephen Esposito, M.D. at New York Presbitarian Hospital (USA) during which he speaks about his clinical uses of FibroScan® for chronic liver disease management.
Discover the interview of Douglas Dieterich, M.D. from Mount Sinai Health System (USA) and how the institution expanded the use of FibroScan® to promote essential screenings